Paolo Gresele

List of Publications by Year
in descending order

343 papers	13,842 citations	18482 62 h-index	30087 103 g-index
349 all docs	349 docs citations	349 times ranked	12885 citing authors

#	Article	IF	Citations
1	Germline <i>GATA2</i> variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation. Haematologica, 2022, 107, 1072-1085.	3.5	6
2	Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway. Haematologica, 2022, 107, 1643-1654.	3.5	3
3	Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis. European Heart Journal, 2022, 43, 504-514.	2.2	27
4	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
5	Multicentre evaluation of 5B9, a monoclonal antiâ€PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2022, 20, 252-259.	3.8	5
6	Increased plasma PCSK-9 is associated with restenosis in patients undergoing carotid endarterectomy. Internal and Emergency Medicine, 2022, , 1.	2.0	0
7	Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study. Internal and Emergency Medicine, 2022, 17, 1065-1071.	2.0	1
8	Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination. International Journal of Infectious Diseases, 2022, 116, 154-156.	3.3	11
9	Proline-rich tyrosine kinase Pyk2 regulates deep vein thrombosis. Haematologica, 2022, 107, 1374-1383.	3.5	7
10	The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper. Frontiers in Cardiovascular Medicine, 2022, 9, 762443.	2.4	7
11	Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression. Thrombosis Research, 2022, 213, 170-172.	1.7	10
12	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	1.9	13
13	Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding.. Blood Transfusion, 2022, , .	0.4	5
14	Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).. Blood Transfusion, 2022, , .	0.4	2
15	<scp>Antiâ€severe acute respiratory syndrome coronavirusâ€2</scp> adenoviralâ€vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers. British Journal of Haematology, 2022, 198, 257-266.	2.5	12
16	Release of MMP-2 in the circulation of patients with acute coronary syndromes undergoing percutaneous coronary intervention: Role of platelets. Thrombosis Research, 2022, 216, 84-89.	1.7	1
17	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2022, 20, 2127-2135.	3.8	6
18	The amazing genetic complexity of anucleated platelets. , 2022, 1, .		2

#	Article	IF	Citations
19	Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia. Platelets, 2021, 32, 288-291.	2.3	1
20	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	2.0	21
21	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of SocietÃ Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and SocietÃ Italiana per lo Studio dellâ€™Emostasi e della Trombosi (SISET). Journal of Nephrology, 2021, 34, 31-38.	2.0	6
22	Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients. Journal of Infection, 2021, 82, 186-230.	3.3	20
23	Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 223, 933-944.	4.0	113
24	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. International Journal of Cardiology, 2021, 327, 176-182.	1.7	10
25	Search for SARS-CoV-2 RNA in platelets from COVID-19 patients. Platelets, 2021, 32, 284-287.	2.3	28
26	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	3.8	40
27	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Internal and Emergency Medicine, 2021, 16, 1583-1591.	2.0	9
28	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	3.4	14
29	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	2.7	3
30	Effect of First Long-Term Training on Whole Blood Count and Blood Clotting Parameters in Thoroughbreds. Animals, 2021, 11, 447.	2.3	10
31	Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias. Journal of Clinical Medicine, 2021, 10, 533.	2.4	14
32	Guidance on the diagnosis and management of PTâ€VWD: A communication from the platelet physiology subcommittee of the ISTHâ€•REPLY to Comment on the diseaseâ€™ nomenclature. Journal of Thrombosis and Haemostasis, 2021, 19, 866-867.	3.8	0
33	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
34	Walking-induced endothelial dysfunction predicts ischemic cardiovascular events in patients with intermittent claudication. Vascular Medicine, 2021, 26, 394-400.	1.5	3
35	Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications. Hamostaseologie, 2021, 41, 136-145.	1.9	4
36	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3

#	Article	IF	Citations
37	Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis. TH Open, 2021, 05, e295-e302.	1.4	13
38	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica, 2021, 106, 3034-3045.	3.5	24
39	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	3.8	20
40	Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Advances, 2021, 5, 5453-5467.	5.2	12
41	Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfusion, 2021, 19, 281-283.	0.4	24
42	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	1.7	35
43	A p.Arg127Gln variant in GPIbÎ± LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD. Blood Advances, 2021, , .	5.2	4
44	Comparative evaluation of the fully automated HemosIL^{Â®} AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13. Clinical Chemistry and Laboratory Medicine, 2021, 59, e193-e196.	2.3	1
45	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2021, 19, 14-23.	0.4	4
46	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
47	Nextâ€generation sequencing for the diagnosis ofMYH9â€RD: Predicting pathogenic variants. Human Mutation, 2020, 41, 277-290.	2.5	30
48	Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica, 2020, 105, 820-828.	3.5	51
49	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102103.	3.3	16
50	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
51	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	1.8	3
52	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
53	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	3.4	131
54	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7

#	Article	IF	Citations
55	Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma. Internal and Emergency Medicine, 2020, 15, 1169-1181.	2.0	7
56	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
57	Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer. International Journal of Hematology, 2020, 112, 725-727.	1.6	6
58	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. Gerontology, 2020, 66, 447-459.	2.8	4
59	Guidance on the diagnosis and management of plateletâ€type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 1855-1858.	3.8	17
60	FVIII/VWF complex displays a greater proâ€haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cellâ€based models. Haemophilia, 2020, 26, e151-e160.	2.1	2
61	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2020, 18, 167-169.	0.4	247
62	Randomized Trial of HymovisÂ® versus SynviscÂ® on Matrix Metalloproteinases in Knee Osteoarthritis. Muscles, Ligaments and Tendons Journal, 2020, 10, 553.	0.3	1
63	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
64	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. Blood Transfusion, 2020, 18, 478-485.	0.4	2
65	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. Angiology, 2019, 70, 257-263.	1.8	21
66	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS ONE, 2019, 14, e0219676.	2.5	16
67	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	1.6	20
68	Inherited platelet disorders in women. Thrombosis Research, 2019, 181, S54-S59.	1.7	5
69	Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs. Thrombosis Research, 2019, 175, 1-5.	1.7	4
70	Mechanisms of thrombocytopenia in platelet-type von Willebrand disease. Haematologica, 2019, 104, 1473-1481.	3.5	31
71	Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. Biochemical Pharmacology, 2019, 166, 300-312.	4.4	56
72	Curated diseaseâ€causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1253-1260.	3.8	56

#	Article	IF	Citations
73	Eltrombopag in preparation for surgery in patients with severe MYH9â€related thrombocytopenia. American Journal of Hematology, 2019, 94, E199-E201.	4.1	20
74	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	2.7	43
75	Platelet function assays in diagnosis: an update. Expert Review of Hematology, 2019, 12, 29-46.	2.2	30
76	PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. Thrombosis and Haemostasis, 2019, 119, 359-367.	3.4	58
77	Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors. European Heart Journal, 2019, 40, 392-392.	2.2	5
78	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
79	A novel variant Glanzmann thrombasthenia due to co-inheritance of a loss- and a gain-of-function mutation of ITGB3 : evidence of a dominant effect of gain-of-function mutations. Haematologica, 2018, 103, e259-e263.	3.5	16
80	Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. International Journal of Cardiology, 2018, 263, 118-124.	1.7	13
81	Anti-platelet treatments in cancer: Basic and clinical research. Thrombosis Research, 2018, 164, S106-S111.	1.7	16
82	Coronary and peripheral artery atherosclerosis. Journal of Cardiovascular Medicine, 2018, 19, e72-e74.	1.5	2
83	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	1.8	35
84	Prochemerin cleavage by factor XIa links coagulation and inflammation. Blood, 2018, 131, 353-364.	1.4	31
85	A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli. Thrombosis Research, 2018, 172, 110-118.	1.7	18
86	Of mice and men: genes relevant to thrombosis and bleeding. Blood, 2018, 132, 2532-2534.	1.4	0
87	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2341-2346.	3.8	11
88	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	1.6	12
89	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	1.4	573
90	Laboratory diagnosis of clinically relevant platelet function disorders. International Journal of Laboratory Hematology, 2018, 40, 34-45.	1.3	24

#	Article	IF	Citations
91	Bioactive lipid metabolism in platelet â€œfirst responderâ€•and cancer biology. Cancer and Metastasis Reviews, 2018, 37, 439-454.	5.9	14
92	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
93	Platelets and Airway Diseases. , 2017, , 1149-1168.		4
94	Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood, 2017, 130, 527-536.	1.4	64
95	The Migration of Platelets and their Interaction with Other Migrating Cells. , 2017, , 337-351.		7
96	A novel mechanism regulating human platelet activation by MMP-2â€“mediated PAR1 biased signaling. Blood, 2017, 129, 883-895.	1.4	62
97	Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?. Haematologica, 2017, 102, e431-e433.	3.5	15
98	Platelet â€œfirst respondersâ€•in wound response, cancer, and metastasis. Cancer and Metastasis Reviews, 2017, 36, 199-213.	5.9	127
99	Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. Thrombosis Research, 2017, 157, 20-22.	1.7	4
100	Platelet-targeted pharmacologic treatments as anti-cancer therapy. Cancer and Metastasis Reviews, 2017, 36, 331-355.	5.9	38
101	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. Thrombosis and Haemostasis, 2017, 117, 2116-2124.	3.4	20
102	Matrix Metalloproteinases and Platelet Function. Progress in Molecular Biology and Translational Science, 2017, 147, 133-165.	1.7	39
103	Dipyridamole and PDE Inhibitors. , 2017, , 1283-1298.		3
104	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	2.5	21
105	Two novel ITGA2B mutations in a Glanzmann thrombasthaenia family associated with different platelet phenotypic expression. Blood Transfusion, 2017, 15, 487-488.	0.4	0
106	Inherited platelet function disorders. Hamostaseologie, 2016, 36, 265-278.	1.9	16
107	Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease. Ear and Hearing, 2016, 37, 112-120.	2.1	24
108	Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica, 2016, 101, 46-56.	3.5	50

#	Article	IF	Citations
109	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
110	First Diagnosis of Hemophilia B in a Nonagenarian. Journal of the American Geriatrics Society, 2016, 64, 230-231.	2.6	1
111	Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions. Thrombosis and Haemostasis, 2016, 115, 333-343.	3.4	12
112	Reasons for Visits to an Emergency Center and Hemostatic Alterations in Patients with Recurrent Spontaneous Subconjunctival Hemorrhage. European Journal of Ophthalmology, 2016, 26, 188-192.	1.3	6
113	Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 411-414.	3.8	26
114	Inherited Platelet Function Disorders: Algorithms for Phenotypic and Genetic Investigation. Seminars in Thrombosis and Hemostasis, 2016, 42, 292-305.	2.7	52
115	Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage. Clinical Chemistry and Laboratory Medicine, 2016, 54, 97-103.	2.3	7
116	A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thrombosis and Haemostasis, 2015, 114, 14-25.	3.4	82
117	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. Gastroenterology Research and Practice, 2015, 2015, 1-7.	1.5	11
118	RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. Journal of Allergy and Clinical Immunology, 2015, 135, 528-538.e4.	2.9	60
119	Effect of substituted stilbenes on platelet function. FÃ¬toterapÃ¬Ã¢, 2015, 105, 228-233.	2.2	30
120	Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. Blood, 2015, 125, 697-705.	1.4	29
121	Î±IIbÎ²3 variants defined by next-generation sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1898-907.	7.1	36
122	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thrombosis Research, 2015, 135, 46-49.	1.7	70
123	Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 314-322.	3.8	220
124	Modeling CD40-Based Molecular Communications in Blood Vessels. IEEE Transactions on Nanobioscience, 2014, 13, 230-243.	3.3	48
125	Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A pilot study of inflammation, endothelial dysfunction, and coagulation markers. Scandinavian Journal of Infectious Diseases, 2014, 46, 466-470.	1.5	9
126	MYH9-Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype Correlations. Human Mutation, 2014, 35, 236-247.	2.5	154

#	Article	IF	Citations
127	THU0194â€...Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study. Annals of the Rheumatic Diseases, 2014, 73, 248.3-249.	0.9	1
128	Stimulation of Platelet Nitric Oxide Production by Nebivolol Prevents Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 820-829.	2.4	35
129	Possible incorrect genotyping of heterozygous factor V Leiden and Prothrombin 20210 gene mutations by the GeneXpert assay. Clinica Chimica Acta, 2014, 435, 36-39.	1.1	1
130	A novel congenital dysprothrombinemia leading to defective prothrombin maturation. Thrombosis Research, 2014, 134, 1135-1141.	1.7	18
131	Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. Journal of Thrombosis and Haemostasis, 2014, 12, 1562-1569.	3.8	139
132	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood, 2014, 124, e4-e10.	1.4	112
133	Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Thrombosis and Haemostasis, 2014, 111, 1089-1101.	3.4	22
134	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	3.5	63
135	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. International Journal of Cardiology, 2013, 168, 981-986.	1.7	46
136	Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. Journal of Thrombosis and Thrombolysis, 2013, 35, 178-184.	2.1	14
137	Simulating an in vitro experiment on nanoscale communications by using BiNS2. Nano Communication Networks, 2013, 4, 172-180.	2.9	80
138	In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thrombosis and Haemostasis, 2013, 110, 349-357.	3.4	60
139	Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. British Journal of Haematology, 2013, 162, 112-119.	2.5	86
140	Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2. Blood, 2013, 121, 648-657.	1.4	38
141	Reperfusion of cerebral artery thrombosis by the GPIbâ€“VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood, 2013, 121, 5088-5097.	1.4	61
142	AB0952â€...Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis. Annals of the Rheumatic Diseases, 2013, 71, 693.3-693.	0.9	0
143	Apparent genotypeâ€“phenotype mismatch in a patient with MYH9-related disease: When the exception proves the rule. Thrombosis and Haemostasis, 2013, 110, 618-620.	3.4	6
144	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 901-908.	3.4	37

#	Article	IF	Citations
145	Antiplatelet agents in clinical practice and their haemorrhagic risk. Blood Transfusion, 2013, 11, 349-56.	0.4	20
146	Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovascular Research, 2012, 94, 428-438.	3.8	46
147	Endothelial and platelet function alterations in HIV-infected patients. Thrombosis Research, 2012, 129, 301-308.	1.7	69
148	Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V. Handbook of Experimental Pharmacology, 2012, , 287-309.	1.8	22
149	Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. International Journal of Cardiology, 2012, 160, 149-151.	1.7	4
150	Heparin in the Prophylaxis and Treatment of Venous Thromboembolism and Other Thrombotic Diseases. Handbook of Experimental Pharmacology, 2012, , 179-209.	1.8	10
151	Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. Journal of Vascular Surgery, 2012, 56, 1622-1628.e5.	1.1	18
152	Outside-In Signalling Generated by a Constitutively Activated Integrin Î±IIbÎ²3 Impairs Proplatelet Formation in Human Megakaryocytes. PLoS ONE, 2012, 7, e34449.	2.5	58
153	Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. PLoS ONE, 2012, 7, e35986.	2.5	38
154	The platelet count in EDTAâ€anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories. American Journal of Hematology, 2012, 87, 727-728.	4.1	8
155	Contribution of matrix metalloproteinase 2 to joint destruction in group B Streptococcusâ€“induced murine arthritis. Arthritis and Rheumatism, 2012, 64, 1089-1097.	6.7	22
156	Coinheritance of three novel FV gene mutations in a patient with a severe FV deficiency. Haemophilia, 2012, 18, e51-3.	2.1	6
157	In vitro effect of anti-Î²2 Glycoprotein I antibodies on P-selectin expression, a marker of platelet activation. Reumatismo, 2012, 64, 35-9.	0.9	3
158	Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia -affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation. Thrombosis and Haemostasis, 2011, 105, 921-924.	3.4	4
159	Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets, 2011, 22, 179-187.	2.3	22
160	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 2011, 118, 4714-4718.	1.4	404
161	Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood, 2011, 118, 1903-1911.	1.4	134
162	Response: MMP-9 in platelets: maybe, maybe not. Blood, 2011, 118, 6471-6473.	1.4	8

#	Article	IF	Citations
163	Antiâ€platelet therapy: phosphodiesterase inhibitors. British Journal of Clinical Pharmacology, 2011, 72, 634-646.	2.4	236
164	Inhibition of COX-1 activity and COX-2 expression by 3-(4â€²-geranyloxy-3â€²-methoxyphenyl)-2-trans propenoic acid and its semi-synthetic derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5995-5998.	2.2	14
165	Critical limb ischemia. Internal and Emergency Medicine, 2011, 6, 129-134.	2.0	20
166	Effects of resveratrol and other wine polyphenols on vascular function: an update. Journal of Nutritional Biochemistry, 2011, 22, 201-211.	4.2	144
167	Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. European Heart Journal, 2011, 32, 316-325.	2.2	60
168	Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 121-128.	2.8	12
169	Impact of Tenofovir Versus Abacavir on HIV-Related Endothelial Dysfunction. AIDS Patient Care and STDs, 2011, 25, 567-569.	2.5	9
170	Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2072-H2079.	3.2	25
171	Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica, 2010, 95, 1021-1024.	3.5	51
172	Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood, 2010, 116, 5832-5837.	1.4	141
173	Matrix metalloproteinases and peripheral arterial disease. Internal and Emergency Medicine, 2010, 5, 13-25.	2.0	86
174	Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir. Journal of the International AIDS Society, 2010, 13, P62-P62.	3.0	1
175	Clinical course of highâ€risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2010, 8, 237-242.	3.8	527
176	Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thrombosis and Haemostasis, 2010, 103, 56-61.	3.4	71
177	Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide-Donating Agent. Diabetes Care, 2010, 33, 1262-1268.	8.6	40
178	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thrombosis Research, 2010, 126, 150-153.	1.7	30
179	Eltrombopag for the Treatment of the Inherited Thrombocytopenia Deriving From MYH9 Mutations. Blood, 2010, 116, 2533-2533.	1.4	1
180	Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. Journal of Experimental Medicine, 2009, 206, 2365-2379.	8.5	80

#	Article	IF	Citations
181	HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. Aids, 2009, 23, 589-596.	2.2	114
182	Perioperative handling of antiplatelet therapy: watching the two sides of the coin. Internal and Emergency Medicine, 2009, 4, 275-276.	2.0	4
183	Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thrombosis Research, 2009, 123, 444-451.	1.7	52
184	Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e6-e12.	1.7	47
185	Plasma levels of Î²2-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. Atherosclerosis, 2009, 203, 38-40.	0.8	8
186	Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level Functional and modelling studies. Thrombosis and Haemostasis, 2009, 102, 336-346.	3.4	63
187	Dominant inheritance of a novel integrin Â3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica, 2009, 94, 663-669.	3.5	64
188	Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. Journal of Cell Biology, 2009, 187, i2-i2.	5.2	0
189	Effects of dietary protein restriction on albumin and fibrinogen synthesis in macroalbuminuric type 2 diabetic patients. Diabetologia, 2008, 51, 21-28.	6.3	20
190	A new case of acquired Glanzmann's thrombasthenia: Diagnostic value of flow cytometry. Cytometry Part B - Clinical Cytometry, 2008, 74B, 194-199.	1.5	33
191	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history ofMYH9-related disease. Human Mutation, 2008, 29, 409-417.	2.5	172
192	TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. Thrombosis Research, 2008, 121, 763-768.	1.7	23
193	Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends in Pharmacological Sciences, 2008, 29, 352-360.	8.7	67
194	The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?. European Heart Journal, 2008, 30, 131-132.	2.2	10
195	Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease. Family Practice, 2008, 25, 228-232.	1.9	27
196	Allergen Induces the Migration of Platelets to Lung Tissue in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 604-612.	5.6	147
197	Resveratrol, at Concentrations Attainable with Moderate Wine Consumption, Stimulates Human Platelet Nitric Oxide Production3. Journal of Nutrition, 2008, 138, 1602-1608.	2.9	133
198	A Comparison of Lupus Anticoagulantâ€“Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, e309-10.	2.4	43

#	Article	IF	Citations
199	Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica, 2007, 92, 1647-1654.	3.5	44
200	Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica, 2007, 92, 812-818.	3.5	92
201	Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thrombosis and Haemostasis, 2007, 97, 444-450.	3.4	46
202	Platelets release active matrix metalloproteinaseâ€2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. British Journal of Haematology, 2007, 138, 221-230.	2.5	51
203	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. Journal of Thrombosis and Haemostasis, 2007, 5, 925-930.	3.8	95
204	NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. European Journal of Pharmacology, 2007, 570, 115-124.	3.5	43
205	Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thrombosis and Haemostasis, 2007, 97, 444-50.	3.4	16
206	Pharmacologic Profile and Therapeutic Potential of NCX 4016, a Nitric Oxide-releasing Aspirin, for Cardiovascular Disorders. Cardiovascular Drug Reviews, 2006, 24, 148-168.	4.1	45
207	Nitric oxide-donating aspirin (NCXÂ4016): an overview of its pharmacological properties and clinical perspectives. European Journal of Clinical Pharmacology, 2006, 62, 145-154.	1.9	24
208	Selective Cytochrome c Displacement by Phosphate and Ca2+ in Brain Mitochondria. Journal of Membrane Biology, 2006, 212, 199-210.	2.1	5
209	Defective plateletÎ²-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders. Platelets, 2006, 17, 20-29.	2.3	15
210	Usefulness of lyophilized calibration plasmas for International Normalized Ratio determination with the bovine combined thromboplastin (Thrombotest): results of a collaborative study. Blood Coagulation and Fibrinolysis, 2005, 16, 157-163.	1.0	4
211	Î²1-tubulin in human platelets: not simply a structural cell frame. Blood, 2005, 106, 2229-2230.	1.4	2
212	A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression1. Journal of Thrombosis and Haemostasis, 2005, 3, 2554-2562.	3.8	51
213	Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. Journal of Thrombosis and Haemostasis, 2005, 3, 2526-2535.	3.8	65
214	Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thrombosis and Haemostasis, 2005, 93, 535-543.	3.4	40
215	Nitric Oxide and its Antithrombotic Action in the Cardiovascular System. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 65-74.	2.0	31
216	Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016). Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1331-1337.	2.5	29

#	Article	IF	Citations
217	Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood, 2005, 105, 2074-2081.	1.4	190
218	Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment. Haematologica, 2005, 90, 1720-2.	3.5	3
219	Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?. European Heart Journal, 2004, 25, 1769-1771.	2.2	7
220	Binding and Release of Cytochrome c in Brain Mitochondria Is Influenced by Membrane Potential and Hydrophobic Interactions with Cardiolipin. Journal of Membrane Biology, 2004, 198, 43-53.	2.1	28
221	Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood, 2004, 103, 639-647.	1.4	135
222	Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology, 2003, 38, 230-237.	7.3	124
223	Platelets are essential for leukocyte recruitment in allergic inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, 109-118.	2.9	197
224	Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. Journal of the American College of Cardiology, 2003, 41, 1013-1020.	2.8	237
225	NCX4016: a novel antithrombotic agent. Digestive and Liver Disease, 2003, 35, S20-S26.	0.9	9
226	Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterology, 2003, 124, 600-607.	1.3	211
227	Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. Biochemical and Biophysical Research Communications, 2003, 311, 897-903.	2.1	17
228	Title is missing!. Medicine (United States), 2003, 82, 203-215.	1.0	30
229	MYH9-Related Disease. Medicine (United States), 2003, 82, 203-215.	1.0	255
230	Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica, 2003, 88, 582-92.	3.5	91
231	In vitro assays for evaluating platelet function. , 2002, , 459-470.		11
232	Novel approaches to the treatment of thrombosis. Trends in Pharmacological Sciences, 2002, 23, 25-32.	8.7	67
233	Platelets and allergic diseases. , 2002, , 852-868.		7
234	Prostaglandin Endoperoxides and Thromboxane A2 Activate the same Receptor Isoforms in Human Platelets. Thrombosis and Haemostasis, 2002, 87, 114-121.	3.4	40

#	Article	IF	Citations
235	Dynamics of the platelet cytoskeleton. , 2002, , 93-103.		4
236	Platelet signalling: calcium. , 2002, , 260-271.		13
237	Platelet signalling: cAMP and cGMP. , 2002, , 290-303.		5
238	Amplification loops: release reaction. , 2002, , 357-368.		3
239	Vascular control of platelet function. , 2002, , 432-456.		8
240	Flow cytometric analysis of platelet function. , 2002, , 485-498.		6
241	Thrombocytosis and thrombocythemia. , 2002, , 623-638.		1
242	Acquired platelet function defects. , 2002, , 689-706.		4
243	Platelets and chemotaxis. , 2002, , 393-411.		2
244	Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thrombosis and Haemostasis, 2002, 87, 114-21.	3.4	12
245	Platelets in respiratory disorders and inflammatory conditions. , 2001, , 323-340.		0
246	Platelet pharmacology. , 2001, , 341-366.		0
247	Antiplatelet treatment in peripheral arterial disease. , 2001, , 458-470.		0
248	Platelet priming. , 2001, , 53-78.		0
249	Inherited Disorders and Gene Regulation of Platelet Signal Transduction: The Picture Is Expanding. Thrombosis and Haemostasis, 2001, 86, 728-730.	3.4	2
250	Treatment of Intermittent Claudication with Mesoglycan â€“ A Placebo-controlled, Double-blind Study. Thrombosis and Haemostasis, 2001, 86, 1181-1187.	3.4	16
251	Plateletâ€“leukocyteâ€“endothelium cross talk. , 2001, , 106-123.		3
252	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Does not Inhibit In Vitro Thrombolysis by Pharmacological Concentrations of t-PA. Thrombosis and Haemostasis, 2001, 85, 661-666.	3.4	21

#	Article	IF	Citations
253	Salicylates Inhibit T Cell Adhesion on Endothelium Under Nonstatic Conditions: Induction of L-Selectin Shedding by a Tyrosine Kinase-Dependent Mechanism. Journal of Immunology, 2001, 166, 832-840.	0.8	18
254	Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Haematologica, 2001, 86, 297-302.	3.5	16
255	Inherited disorders and gene regulation of platelet signal transduction: the picture is expanding. Thrombosis and Haemostasis, 2001, 86, 728-30.	3.4	0
256	Platelets Release their Lysosomal Content In Vivo in Humans upon Activation. Thrombosis and Haemostasis, 2000, 83, 157-164.	3.4	79
257	Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. European Journal of Pharmacology, 2000, 397, 177-185.	3.5	60
258	Involvement of Platelets in Experimental Mouse Trypanosomiasis: Evidence of Mouse Platelet Cytotoxicity against Trypanosoma equiperdum. Experimental Parasitology, 2000, 95, 136-143.	1.2	9
259	Detrimental Effects of High-Dose Dexamethasone in Severe, Refractory, HIV-Related Thrombocytopenia. Annals of Pharmacotherapy, 2000, 34, 1139-1141.	1.9	3
260	Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. Vascular Medicine, 2000, 5, 83-89.	1.5	7
261	Platelets. , 2000, , 79-123.		1
262	Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. Aids, 2000, 14, 1664-1667.	2.2	5
263	Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. Vascular Medicine, 2000, 5, 83-89.	1.5	2
264	Platelets release their lysosomal content in vivo in humans upon activation. Thrombosis and Haemostasis, 2000, 83, 157-64.	3.4	20
265	Assessment of Occlusion of the Vascular Access in Patients on Chronic Hemodialysis: Comparison of Physical Examination with Continuous-Wave Doppler Ultrasound. Nephron, 1999, 82, 7-11.	1.8	10
266	Endogenous Nitric Oxide Acts as a Natural Antithrombotic Agent In Vivo by Inhibiting Platelet Aggregation in the Pulmonary Vasculature. Thrombosis and Haemostasis, 1999, 81, 961-966.	3.4	72
267	Evidence that cytosolic phospholipase A2is down-regulated by protein kinase C in intact human platelets stimulated with fluoroaluminate. FEBS Letters, 1999, 450, 39-43.	2.8	5
268	PAF levels in saliva are regulated by inflammatory cells. Journal of Periodontal Research, 1998, 33, 237-241.	2.7	9
269	Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochemical Pharmacology, 1998, 56, 1481-1484.	4.4	40
270	Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by Preventing Integrin Activation Induced by Contact With Endothelial Cells. Blood, 1998, 92, 2389-2398.	1.4	41

#	Article	IF	Citations
271	Extrapolation of trial results suggests that aspirin is useful in intermittent claudication. BMJ: British Medical Journal, 1998, 317, 1587-1587.	2.3	3
272	Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.. Journal of Clinical Investigation, 1998, 101, 667-676.	8.2	95
273	Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by Preventing Integrin Activation Induced by Contact With Endothelial Cells. Blood, 1998, 92, 2389-2398.	1.4	0
274	Antivasoconstrictor and Antiaggregatory Activities of Picotamide Unrelated to Thromboxane A2 Antagonism. Thrombosis and Haemostasis, 1997, 78, 1385-1391.	3.4	12
275	Platelet Activation Markers in Patients with Peripheral Arterial Disease. Thrombosis and Haemostasis, 1997, 78, 1434-1437.	3.4	35
276	Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo. Circulation, 1997, 96, 69-75.	1.6	180
277	Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. Thrombosis and Haemostasis, 1997, 78, 1434-7.	3.4	9
278	Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A₂ activation. British Journal of Pharmacology, 1996, 118, 1351-1358.	5.4	12
279	Protein kinase C inhibitors enhance G-protein induced phospholipase A2activation in intact human platelets. FEBS Letters, 1996, 381, 244-248.	2.8	24
280	Smoking and Impaired Endothelium-Dependent Dilatation. New England Journal of Medicine, 1996, 334, 1674-1674.	27.0	76
281	Platelet glycohydrolase activities: Characterization and release. Cell Biochemistry and Function, 1995, 13, 31-39.	2.9	10
282	New pyridazinone derivatives as inhibitors of platelet aggregation. European Journal of Medicinal Chemistry, 1995, 30, 627-631.	5.5	17
283	Effect of NSAIDs on pepsinogen secretion and calcium mobilization in isolated chief cells. American Journal of Physiology - Renal Physiology, 1995, 268, G968-G978.	3.4	5
284	Original Article: Albumin Prevents TxB, Formation from Thrombin-stimulated Human Platelets by Sequestering the Liberated Arachidonic Acid in the Extracellular Space. Platelets, 1995, 6, 381-387.	2.3	11
285	Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Journal of Pharmacology and Experimental Therapeutics, 1995, 275, 1497-505.	2.5	7
286	Interferon-Alpha Is Effective in the Treatment of HIV-1â€“Related, Severe, Zidovudine-Resistant Thrombocytopenia: A Prospective, Placebo-controlled, Double-Blind Trial. Annals of Internal Medicine, 1994, 121, 423.	3.9	26
287	Cloricromene inhibits leukotriene formation by human polymorphonuclear leucocytes by suppressing arachidonate release from membrane phospholipids. Biochemical Pharmacology, 1993, 45, 123-130.	4.4	13
288	The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. British Journal of Pharmacology, 1993, 110, 1565-1571.	5.4	22

#	Article	IF	Citations
289	Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. Journal of Allergy and Clinical Immunology, 1993, 91, 894-902.	2.9	78
290	Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. Gastroenterology, 1993, 105, 170-177.	1.3	36
291	Platelet Thromboxane A₂ Receptor Number and Function in Normal and Hypertensive Pregnancy. American Journal of Reproductive Immunology, 1993, 30, 160-166.	1.2	2
292	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood, 1993, 82, 2704-2713.	1.4	81
293	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood, 1993, 82, 2704-2713.	1.4	1
294	Cloricromene inhibits G-protein-mediated activation of phospholipase A2 in human platelets. Journal of Lipid Mediators, 1993, 7, 253-67.	0.2	3
295	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood, 1993, 82, 2704-13.	1.4	18
296	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology, 1992, 103, 641-646.	1.3	105
297	Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Thrombosis Research, 1992, 66, 259-264.	1.7	6
298	Activation of phospholipase A2 and Î²-thromboglobulin release in human platelets: Comparative effects of thrombin and fluoroaluminate stimulation. Lipids and Lipid Metabolism, 1992, 1124, 279-287.	2.6	17
299	Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends in Pharmacological Sciences, 1991, 12, 158-163.	8.7	117
300	Generation of Arachidonic Acid Metabolites from Stimulated Whole Blood in Patients with Chronic Myeloproliferative Disorders. Acta Haematologica, 1991, 85, 88-92.	1.4	5
301	Red Cell Deformability Alterations in Normal Late Pregnancy: Possible Role of Plasma Components. Gynecologic and Obstetric Investigation, 1991, 32, 213-216.	1.6	2
302	Effect of glyceryl trinitrate on distensibility of peripheral muscular arteries in humans is not mediated by prostaglandins. Cardiovascular Research, 1991, 25, 692-699.	3.8	1
303	Picotamide Protects Mice from Death in a Pulmonary Embolism Model by a Mechanism Independent from Thromboxane Suppression. Thrombosis and Haemostasis, 1990, 64, 080-086.	3.4	35
304	Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thrombosis and Haemostasis, 1990, 64, 80-6.	3.4	11
305	Characterization of N,Nâ€™-bis(3-Picolyl)-4-Methoxy-Isophtalamide (Picotamide) as a Dual Thromboxane Synthase Inhibitor/Thromboxane A2 Receptor Antagonist in Human Platelets. Thrombosis and Haemostasis, 1989, 61, 479-484.	3.4	73
306	Acetylsalicylic acid, BM 13.177 and picotamide improve the survival of endotoxin-infused rabbits. Thrombosis Research, 1988, 52, 487-492.	1.7	5

#	Article	IF	Citations
307	Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 301-7.	2.5	28
308	Choline plasmalogen biosynthesis by transmethylation in human platelets. Thrombosis Research, 1987, 45, 687-693.	1.7	10
309	L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood. Biochemical Pharmacology, 1987, 36, 3529-3531.	4.4	17
310	In vitro and ex vivo effects of indobufen on red blood cell deformability. European Journal of Clinical Pharmacology, 1987, 32, 207-210.	1.9	8
311	Evidence for Platelet Activation in Allergic Asthma. , 1987, 21, 119-128.		10
312	Dipyridamole Inhibits Leukotriene B4 Synthesis. Thrombosis and Haemostasis, 1987, 57, 235-235.	3.4	9
313	Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.. Journal of Clinical Investigation, 1987, 80, 1435-1445.	8.2	101
314	Dipyridamole inhibits leukotriene B4 synthesis. Thrombosis and Haemostasis, 1987, 57, 235.	3.4	3
315	Leukotriene B4 production by stimulated whole blood: Comparative studies with isolated polymorphonuclear cells. Biochemical and Biophysical Research Communications, 1986, 137, 334-342.	2.1	57
316	Mechanism of the Antiplatelet Action of Dipyridamole in Whole Blood: Modulation of Adenosine Concentration and Activity. Thrombosis and Haemostasis, 1986, 55, 012-018.	3.4	108
317	Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thrombosis and Haemostasis, 1986, 55, 12-8.	3.4	29
318	Partial isolation and function of the prostacyclin regulating plasma factor. Clinical Science, 1985, 69, 383-393.	4.3	25
319	COMBINING ANTIPLATELET AGENTS: POTENTIATION BETWEEN ASPIRIN AND DIPYRIDAMOLE. Lancet, The, 1985, 325, 937-938.	13.7	11
320	PLATELETS AND ASTHMA. Lancet, The, 1985, 325, 347.	13.7	31
321	THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS. Lancet, The, 1985, 325, 999-1002.	13.7	210
322	Lack of synergism between dazoxiben and dipyridamole following administration to man. Thrombosis Research, 1985, 37, 231-236.	1.7	3
323	Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thrombosis Research, 1985, 40, 161-170.	1.7	15
324	Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. Translational Research, 1985, 106, 534-41.	2.3	5

#	Article	IF	Citations
325	BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN. Lancet, The, 1984, 323, 991-994.	13.7	71
326	PROLONGING PROSTACYCLIN PRODUCTION BY NAFAZATROM OR DIPYRIDAMOLE. Lancet, The, 1984, 324, 410-411.	13.7	37
327	Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochemical Pharmacology, 1984, 33, 2083-2088.	4.4	101
328	Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy?. Thrombosis and Haemostasis, 1984, 52, 364-364.	3.4	44
329	PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER. British Journal of Haematology, 1984, 57, 171-173.	2.5	5
330	Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?. Thrombosis and Haemostasis, 1984, 52, 364.	3.4	7
331	Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer. British Journal of Haematology, 1984, 57, 171-3.	2.5	1
332	Cholinephosphotransferase activity in human platelets. Lipids, 1983, 18, 179-185.	1.7	14
333	Thrombolytic Therapy for Thromboembolism of Vertebrobasilar Artery. Angiology, 1983, 34, 561-571.	1.8	89
334	Dipyridamole Inhibits Platelet Aggregation in Whole Blood. Thrombosis and Haemostasis, 1983, 50, 852-856.	3.4	131
335	Dipyridamole inhibits platelet aggregation in whole blood. Thrombosis and Haemostasis, 1983, 50, 852-6.	3.4	32
336	Ultraviolet spectra of membrane-rich human platelet particulates. Research in Experimental Medicine, 1982, 180, 117-125.	0.7	0
337	ERYTHROCYTE DEFORMABILITY CHANGES IN NORMAL PREGNANCY AND PRE-ECLAMPSIA. British Journal of Haematology, 1982, 52, 340-342.	2.5	16
338	Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. BJOG: an International Journal of Obstetrics and Gynaecology, 1982, 89, 681-682.	2.3	42
339	Platelet activation and allergic asthma. New England Journal of Medicine, 1982, 306, 549.	27.0	15
340	Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment. Cancer Chemotherapy and Pharmacology, 1981, 5, 205-206.	2.3	8
341	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. Thrombosis and Haemostasis, 1981, 46, 572-572.	3.4	10
342	Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica, 1981, 2, 532-8.	0.2	18

#	Article	IF	Citations
343	Mucus-secreting 'signet-ring' cells in CSF revealing the site of primary cancer.. Postgraduate Medical Journal, 1980, 56, 868-870.	1.8	9